Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)

Ajay K Gopal, MD, Andrew John Davies, BM, PhD, Ian W. Flinn, MD PhD, Paolo Ghia, MD PhD, Andre Goy, MD, Gilles A. Salles, MD PhD, Steve Abella, MD, Betsy Philip, Bess Sorenson, Nina D. Wagner-Johnston, MD

Blood (2015) 126 (23): 2743.

https://doi.org/10.1182/blood.V126.23.2743.2743

Published: 2015

Journal Articles

Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy

Ajay K Gopal, MD, Brad S Kahl, MD, Christopher Flowers, MD, Peter Martin, MD, Brian K Link, MD, Stephen Ansell, MD PhD, Wei Ye, Brian Koh, MD, Steve Abella, MD, Paul M. Barr, MD, Gilles A. Salles, MD PhD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 2744.

https://doi.org/10.1182/blood.V126.23.2744.2744

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 4152.

https://doi.org/10.1182/blood.V126.23.4152.4152

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Peter Martin, MD, Armando Armas, MD, Ajay K Gopal, MD, Emmanuel Gyan, MD PhD, Nina D. Wagner-Johnston, MD, Jan Walewski, MDPhDProf, Steve Abella, MD, Wei Ye, Betsy Philip, Bess Sorenson, Sven de Vos, MD PhD

Blood (2015) 126 (23): 1543.

https://doi.org/10.1182/blood.V126.23.1543.1543

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Clarence Eng, MPH, Jing He, Jing Hu, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 1545.

https://doi.org/10.1182/blood.V126.23.1545.1545

Published: 2015

Journal Articles

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mark D. Minden, MD PhD, Wendy Stock, MD, Howland Crosswell, MD, Robert D Siegel, MD, Patrick Chun, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Dan Douer, MD

Blood (2015) 126 (23): 4866.

https://doi.org/10.1182/blood.V126.23.4866.4866

Published: 2015

Journal Articles

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak

Blood (2015) 125 (15): 2336–2343.

https://doi.org/10.1182/blood-2014-08-595934

Published: 2015

Includes: Supplemental data

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Steve Abella, MD, Meihua Wu, PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 4419.

https://doi.org/10.1182/blood.V124.21.4419.4419

Published: 2014

Journal Articles

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Kam Cheung, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy, Mary K Stanton, Tammy L Bush, Richard L Kendall, Robert Radinsky, Steve Abella, Peter C Pieslor, Gregory Friberg, Angela Coxon, Erick Gamelin, Marc Payton

Blood (2013) 122 (21): 3823.

https://doi.org/10.1182/blood.V122.21.3823.3823

Published: 2013

Journal Articles

Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy

Lodovico Balducci, MD, May Mo, PhD, Steve Abella, MD, Alan Saven, MD

Blood (2012) 120 (21): 4880.

https://doi.org/10.1182/blood.V120.21.4880.4880

Published: 2012

Journal Articles

Underreporting of Myelotoxicity with Emerging Regimens for Selected Hematologic Malignancies

Stephanie A. Gregory, MD, Steve Abella, MD, Timothy Moore, MD

Blood (2010) 116 (21): 1501.

https://doi.org/10.1182/blood.V116.21.1501.1501

Published: 2010

NARROW

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)

Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy

Underreporting of Myelotoxicity with Emerging Regimens for Selected Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only